# Adebrelimab + Apatinib in SCLC Maintenance Therapy

> **NCT06475209** · PHASE2 · RECRUITING · sponsor: **Tang-Du Hospital** · enrollment: 60 (estimated)

## Conditions studied

- SCLC

## Interventions

- **DRUG:** Adebrelimab combined with Apatinib

## Key facts

- **NCT ID:** NCT06475209
- **Lead sponsor:** Tang-Du Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-20
- **Primary completion:** 2025-12-20
- **Final completion:** 2026-12-20
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-06-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06475209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06475209, "Adebrelimab + Apatinib in SCLC Maintenance Therapy". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06475209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*